Glenmark Pharmaceuticals Ltd., a global, research-driven pharmaceutical company, has announced the launch of Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, the world’s first nebulized, fixed-dose triple therapy developed for patients with Chronic Obstructive Pulmonary Disease (COPD). The introduction of these therapies marks a significant advancement in respiratory care and positions Glenmark at the forefront of innovation in the COPD treatment landscape.
The new Smartules® combine three established COPD medications—Glycopyrronium, Formoterol, and Budesonide—into a single nebulized formulation. This fixed-dose combination is designed to improve lung function, reduce airway inflammation, and enhance day-to-day symptom control. Glenmark noted that the therapy aims to simplify treatment for COPD patients who find it difficult to use Metered Dose Inhalers (MDIs) or Dry Powder Inhalers (DPIs), offering an easier and more accessible alternative.
By delivering all three medicines through a nebulizer, the therapy minimizes the need for multiple devices and complex inhalation techniques. Glenmark stated that this approach has the potential to establish a new standard of care, particularly for patients with moderate to severe COPD who require reliable and consistent drug delivery.
